Flashcards: NS5A inhibitors

Ledipasvir/sofosbuvir (trade name Harvoni) is a two-drug combination for the treatment of hepatitis C.

Ledipasvir (formerly GS-5885) is a drug for the treatment of hepatitis C that was developed by Gilead Sciences.

Deleobuvir (formerly BI 207127) was an experimental drug for the treatment of hepatitis C.

Ombitasvir is an antiviral drug for the treatment of hepatitis C virus (HCV) infection.

Velpatasvir is an inhibitor of NS5A used together with sofosbuvir in the treatment of hepatitis C infection of all six major genotypes.

Velpatasvir/sofosbuvir (trade name Epclusa) is a two-drug combination for the treatment of hepatitis C.

Daclatasvir (trade name Daklinza) is a drug for the treatment of hepatitis C (HCV).

Ravidasvir (PPI-668) is an investigational NS5A inhibitor in clinical trials for chronic hepatitis C genotype 4.

Odalasvir (INN, previously known as ACH-3102) is an investigational new drug in development for the treatment of hepatitis C.

Daclatasvir/sofosbuvir (trade name Darvoni) is a two-drug combination for the treatment of hepatitis C.

Samatasvir (IDX-719) is an experimental drug for the treatment of hepatitis C.